Clinical Trial Update: LIFSCREEN : Evaluation of Whole Body MRI for Early Detection of Cancers in Subjects With P53 Mutation (Li-Fraumeni Syndrome) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating whole-body MRI for early cancer detection in Li-Fraumeni syndrome subjects has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Li-fraumeni Syndrome

Snippet

Sponsor: Gustave Roussy, Cancer Campus, Grand Paris | Conditions: Li Fraumeni Syndrome | Phase 3 | Status: COMPLETED